Table 1. Characteristics of patients with HCV genotype 3 infection who received a sofosbuvir containing treatment regime (n = 316).
| All (N = 316) |
SOF+RBV 24 w (N = 33) |
SOF+pegIFN+RBV 12 w (N = 56) |
SOF/LDV+RBV 12–24 w (N = 32) |
SOF+DCV +/-RBV 12–24 w (N = 195) |
|
|---|---|---|---|---|---|
| Mean age–yr | 55 | 55 | 52 | 51 | 56 |
| Male sex–no. (%) | 220(70.1) | 23 (69.7) | 40 (72.7) | 22 (71.0) | 135 (69.2) |
| Treatment experienced–no. (%) | 154 (49.7) | 20 (62.5) | 23 (41.1) | 11 (34.4) | 101 (51.8) |
| Cirrhosis–no. (%) | 212 (68.2) | 23 (69.7) | 29(74.2) | 22 (73.3) | 139 (73.2) |
| Child Pugh–no (%)* | |||||
| A | 148 (45.9%) | 11 (33.3) | 26 (46.4) | 16 (50%) | 95 (48.7) |
| B | 29 (9.2) | 5 (15.2) | 3 (5.4) | 3 (9.4) | 18 (9.2) |
| C | 11 (3.4) | 6 (18.2) | 0 | 1 (3.1) | 4 (2.1) |
*Child Pugh score was available for 188 out of 212 with cirrhosis.